Do you know all the possible players in the drug and medicine supply chain?
Which are the requirements for each type of actor in the supply chain?
What are the key indicators to be assessed during an audit?
How to approach the audit to distributors, transport and logistic operator?
Distribution networks for medicinal products have become increasingly complex, with the involvement of many players, especially since the rise of globalization in the 1990s. The main problem that has arisen from these changes is that the control over the logistics chain has become much more complicated, especially taking into account the characteristics of the products, which can be sensitive to heat, humidity and light in many cases.
In practice, companies’ Qualified Persons (QPs) did not have an adequate degree of control about what was occurring in the supply chain. However, they had to answer to the Health Authorities for incidents, and also during inspections.
This is the main reason why Good Distribution Practices (GDP) were created, seeking to align requirements and facilitate compliance with regulations, always with the aim of ensuring the safety, quality and traceability of the products throughout the integrated supply chain.
At AFA, we understand the supplier evaluation process as something that goes way beyond auditing. To carry out this process as a mere formality, without strategic vision, is little less than dooming oneself to having problems in the future. These problems can be regulatory, economic and brand prestige, to name a few. The sooner the potential gaps are detected, the lower the overall cost for all the parties involved.
In this webinar we will provide about the clues to approach efficiently the audits to the players of supply chain.
Technical staff from API, and Pharmaceutical industry
Non AFA affiliates: 120 euros
AFA affiliates: 110 euros
(* Applicable Taxes, if any, not included)